Home
Live Updates
NewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023 : comparemela.com
NewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate
Related Keywords
Brooklyn ,
Florida ,
United States ,
Netherlands ,
Miami ,
Naarden ,
Noord Holland ,
Russia ,
Ukraine ,
Hannah Deresiewicz ,
Christiem Ballantyne ,
Matthew Philippe ,
Company Phase ,
Exchange Commission ,
Company Contact ,
Cardiovascular Research ,
Frazier Lifesciences Acquisition Corporation ,
National Lipid Association ,
Neither The Company ,
Newamsterdam Pharma Companynv Nasdaq ,
Baylor College Of Medicine ,
Menarini Group ,
Primary Endpoint ,
Median Reduction ,
Patients Treated ,
Ezetimibe Met Guideline Recommended ,
Data Demonstrate Statistically Significant ,
Clinically Meaningful Improvements ,
Additional Lipid ,
Lipoprotein Parameters Predictive ,
Cardiovascular Disease Risk ,
Tolerability Observed ,
Fixed Dose Combination Tablet Formula ,
Host Conference Call ,
Scientific Sessions ,
Consensus Decision Pathway ,
Baylor College ,
Full Data ,
Conference Call ,
Frazier Healthcare ,
Investor Relations ,
Newamsterdam ,
Dharma ,
Company ,
Presents ,
Bull ,
Data ,
Rom ,
Hase ,
Ose2 ,
Trial ,
Valuating ,
Bicetrapib ,
Combination ,
Ezetimibe ,
Adjunct ,
Thigh ,
Intensity ,
Statin ,
Therapy ,
Cientific ,
Sessions ,
023 ,
comparemela.com © 2020. All Rights Reserved.